Impact  ||| S:0 E:7 ||| NN
of  ||| S:7 E:10 ||| IN
cardiac  ||| S:10 E:18 ||| JJ
magnetic  ||| S:18 E:27 ||| JJ
resonance  ||| S:27 E:37 ||| NN
imaging  ||| S:37 E:45 ||| NN
for  ||| S:45 E:49 ||| IN
assessment  ||| S:49 E:60 ||| NN
of  ||| S:60 E:63 ||| IN
Churg-Strauss  ||| S:63 E:77 ||| JJ
syndrome ||| S:77 E:85 ||| NN
:  ||| S:85 E:87 ||| :
a  ||| S:87 E:89 ||| DT
cross-sectional  ||| S:89 E:105 ||| JJ
study  ||| S:105 E:111 ||| NN
in  ||| S:111 E:114 ||| IN
20  ||| S:114 E:117 ||| CD
patients  ||| S:117 E:126 ||| NNS
To  ||| S:126 E:129 ||| TO
examine  ||| S:129 E:137 ||| VB
the  ||| S:137 E:141 ||| DT
diagnostic  ||| S:141 E:152 ||| JJ
contributions  ||| S:152 E:166 ||| NNS
of  ||| S:166 E:169 ||| IN
cardiac  ||| S:169 E:177 ||| JJ
magnetic  ||| S:177 E:186 ||| JJ
resonance  ||| S:186 E:196 ||| NN
imaging  ||| S:196 E:204 ||| NN
( ||| S:204 E:205 ||| -LRB-
CMRI ||| S:205 E:209 ||| NNP
)  ||| S:209 E:211 ||| -RRB-
with  ||| S:211 E:216 ||| IN
delayed-enhancement  ||| S:216 E:236 ||| NNP
( ||| S:236 E:237 ||| -LRB-
DE ||| S:237 E:239 ||| NNP
)  ||| S:239 E:241 ||| -RRB-
in  ||| S:241 E:244 ||| IN
patients  ||| S:244 E:253 ||| NNS
with  ||| S:253 E:258 ||| IN
Churg-Strauss  ||| S:258 E:272 ||| JJ
syndrome  ||| S:272 E:281 ||| NN
( ||| S:281 E:282 ||| -LRB-
CSS ||| S:282 E:285 ||| NNP
) ||| S:285 E:286 ||| -RRB-
.  ||| S:286 E:288 ||| .
We  ||| S:288 E:291 ||| PRP
consecutively  ||| S:291 E:305 ||| VBP
recruited  ||| S:305 E:315 ||| VBN
14  ||| S:315 E:318 ||| CD
men  ||| S:318 E:322 ||| NNS
and  ||| S:322 E:326 ||| CC
6  ||| S:326 E:328 ||| CD
women  ||| S:328 E:334 ||| NNS
( ||| S:334 E:335 ||| -LRB-
mean  ||| S:335 E:340 ||| JJ
age ||| S:340 E:343 ||| NN
:  ||| S:343 E:345 ||| :
50+ ||| S:345 E:348 ||| CD
/ ||| S:348 E:349 ||| CD
-14  ||| S:349 E:353 ||| CD
years ||| S:353 E:358 ||| NNS
)  ||| S:358 E:360 ||| -RRB-
with  ||| S:360 E:365 ||| IN
CSS  ||| S:365 E:369 ||| NNP
( ||| S:369 E:370 ||| -LRB-
mean  ||| S:370 E:375 ||| JJ
disease  ||| S:375 E:383 ||| NN
duration ||| S:383 E:391 ||| NN
:  ||| S:391 E:393 ||| :
4.5+ ||| S:393 E:397 ||| CD
/ ||| S:397 E:398 ||| CD
-3.6  ||| S:398 E:403 ||| CD
years ||| S:403 E:408 ||| NNS
)  ||| S:408 E:410 ||| -RRB-
and  ||| S:410 E:414 ||| CC
investigated  ||| S:414 E:427 ||| VBD
them  ||| S:427 E:432 ||| PRP
independently  ||| S:432 E:446 ||| RB
of  ||| S:446 E:449 ||| IN
the  ||| S:449 E:453 ||| DT
presence ||| S:453 E:461 ||| NN
/ ||| S:461 E:462 ||| CD
absence  ||| S:462 E:470 ||| NN
of  ||| S:470 E:473 ||| IN
cardiac  ||| S:473 E:481 ||| JJ
manifestations ||| S:481 E:495 ||| NNS
.  ||| S:495 E:497 ||| .
Cardiac  ||| S:497 E:505 ||| JJ
manifestations  ||| S:505 E:520 ||| NNS
included  ||| S:520 E:529 ||| VBD
heart  ||| S:529 E:535 ||| NN
failure  ||| S:535 E:543 ||| NN
in  ||| S:543 E:546 ||| IN
6  ||| S:546 E:548 ||| CD
patients ||| S:548 E:556 ||| NNS
,  ||| S:556 E:558 ||| ,
angina  ||| S:558 E:565 ||| JJ
pectoris  ||| S:565 E:574 ||| NN
in  ||| S:574 E:577 ||| IN
1 ||| S:577 E:578 ||| CD
,  ||| S:578 E:580 ||| ,
isolated  ||| S:580 E:589 ||| VBD
ECG  ||| S:589 E:593 ||| NNP
abnormality  ||| S:593 E:605 ||| NN
in  ||| S:605 E:608 ||| IN
1 ||| S:608 E:609 ||| CD
,  ||| S:609 E:611 ||| ,
and  ||| S:611 E:615 ||| CC
isolated  ||| S:615 E:624 ||| JJ
echocardiography  ||| S:624 E:641 ||| NN
and  ||| S:641 E:645 ||| CC
ECG  ||| S:645 E:649 ||| NNP
abnormalities  ||| S:649 E:663 ||| NN
in  ||| S:663 E:666 ||| IN
1 ||| S:666 E:667 ||| CD
.  ||| S:667 E:669 ||| .
T1-weighted  ||| S:669 E:681 ||| NNP
sequences  ||| S:681 E:691 ||| NN
were  ||| S:691 E:696 ||| VBD
recorded  ||| S:696 E:705 ||| VBN
after  ||| S:705 E:711 ||| IN
gadolinium  ||| S:711 E:722 ||| JJ
injection  ||| S:722 E:732 ||| NN
to  ||| S:732 E:735 ||| TO
study  ||| S:735 E:741 ||| VB
myocardial  ||| S:741 E:752 ||| JJ
DE ||| S:752 E:754 ||| NNP
.  ||| S:754 E:756 ||| .
CMRI  ||| S:756 E:761 ||| NNP
abnormalities  ||| S:761 E:775 ||| NN
were  ||| S:775 E:780 ||| VBD
found  ||| S:780 E:786 ||| VBN
in  ||| S:786 E:789 ||| IN
13 ||| S:789 E:791 ||| CD
/ ||| S:791 E:792 ||| CD
20  ||| S:792 E:795 ||| CD
patients ||| S:795 E:803 ||| NNS
,  ||| S:803 E:805 ||| ,
including  ||| S:805 E:815 ||| VBG
all  ||| S:815 E:819 ||| DT
9  ||| S:819 E:821 ||| CD
patients  ||| S:821 E:830 ||| NNS
with  ||| S:830 E:835 ||| IN
myocardial  ||| S:835 E:846 ||| JJ
manifestations ||| S:846 E:860 ||| NNS
,  ||| S:860 E:862 ||| ,
and  ||| S:862 E:866 ||| CC
4  ||| S:866 E:868 ||| CD
of  ||| S:868 E:871 ||| IN
the  ||| S:871 E:875 ||| DT
11  ||| S:875 E:878 ||| CD
asymptomatic  ||| S:878 E:891 ||| CD
patients ||| S:891 E:899 ||| NNS
.  ||| S:899 E:901 ||| .
DE  ||| S:901 E:904 ||| NNP
was  ||| S:904 E:908 ||| VBD
centromyocardial  ||| S:908 E:925 ||| VBN
in  ||| S:925 E:928 ||| IN
6  ||| S:928 E:930 ||| CD
patients ||| S:930 E:938 ||| NNS
,  ||| S:938 E:940 ||| ,
subepicardial  ||| S:940 E:954 ||| VBG
in  ||| S:954 E:957 ||| IN
4 ||| S:957 E:958 ||| CD
,  ||| S:958 E:960 ||| ,
and  ||| S:960 E:964 ||| CC
subendocardial  ||| S:964 E:979 ||| NN
in  ||| S:979 E:982 ||| IN
3 ||| S:982 E:983 ||| CD
.  ||| S:983 E:985 ||| .
Most  ||| S:985 E:990 ||| RBS
enhanced  ||| S:990 E:999 ||| JJ
lesions  ||| S:999 E:1007 ||| NNS
were  ||| S:1007 E:1012 ||| VBD
in  ||| S:1012 E:1015 ||| IN
the  ||| S:1015 E:1019 ||| DT
anteroseptal  ||| S:1019 E:1032 ||| NN
or  ||| S:1032 E:1035 ||| CC
lateral  ||| S:1035 E:1043 ||| JJ
walls ||| S:1043 E:1048 ||| NNS
.  ||| S:1048 E:1050 ||| .
Patients  ||| S:1050 E:1059 ||| NNS
with  ||| S:1059 E:1064 ||| IN
myocardial  ||| S:1064 E:1075 ||| JJ
symptoms  ||| S:1075 E:1084 ||| NNS
and  ||| S:1084 E:1088 ||| CC
DE  ||| S:1088 E:1091 ||| NNP
had  ||| S:1091 E:1095 ||| VBD
higher  ||| S:1095 E:1102 ||| JJR
transmyocardial  ||| S:1102 E:1118 ||| JJ
wall  ||| S:1118 E:1123 ||| NN
DE  ||| S:1123 E:1126 ||| NN
scores  ||| S:1126 E:1133 ||| NNS
( ||| S:1133 E:1134 ||| -LRB-
mean ||| S:1134 E:1138 ||| VB
:  ||| S:1138 E:1140 ||| :
9.4  ||| S:1140 E:1144 ||| CD
vs.  ||| S:1144 E:1148 ||| IN
3.7 ||| S:1148 E:1151 ||| CD
,  ||| S:1151 E:1153 ||| ,
respectively ||| S:1153 E:1165 ||| RB
;  ||| S:1165 E:1167 ||| :
p=0.01 ||| S:1167 E:1173 ||| CD
)  ||| S:1173 E:1175 ||| -RRB-
and  ||| S:1175 E:1179 ||| CC
lower  ||| S:1179 E:1185 ||| JJR
left  ||| S:1185 E:1190 ||| JJ
ventricular  ||| S:1190 E:1202 ||| FW
ejection  ||| S:1202 E:1211 ||| FW
fractions  ||| S:1211 E:1221 ||| FW
( ||| S:1221 E:1222 ||| -LRB-
mean ||| S:1222 E:1226 ||| VB
:  ||| S:1226 E:1228 ||| :
42 ||| S:1228 E:1230 ||| CD
%  ||| S:1230 E:1232 ||| NN
vs.  ||| S:1232 E:1236 ||| IN
59 ||| S:1236 E:1238 ||| CD
% ||| S:1238 E:1239 ||| NN
;  ||| S:1239 E:1241 ||| :
p=0.001 ||| S:1241 E:1248 ||| CD
)  ||| S:1248 E:1250 ||| -RRB-
than  ||| S:1250 E:1255 ||| IN
asymptomatic  ||| S:1255 E:1268 ||| JJ
patients  ||| S:1268 E:1277 ||| NNS
with  ||| S:1277 E:1282 ||| IN
DE ||| S:1282 E:1284 ||| NNP
.  ||| S:1284 E:1286 ||| .
CMRI  ||| S:1286 E:1291 ||| NNP
with  ||| S:1291 E:1296 ||| IN
DE  ||| S:1296 E:1299 ||| NNP
enabled  ||| S:1299 E:1307 ||| VBD
the  ||| S:1307 E:1311 ||| DT
detection  ||| S:1311 E:1321 ||| NN
of  ||| S:1321 E:1324 ||| IN
myocardial  ||| S:1324 E:1335 ||| JJ
involvement  ||| S:1335 E:1347 ||| NN
in  ||| S:1347 E:1350 ||| IN
CSS  ||| S:1350 E:1354 ||| NNP
patients  ||| S:1354 E:1363 ||| NNS
with  ||| S:1363 E:1368 ||| IN
or  ||| S:1368 E:1371 ||| CC
without  ||| S:1371 E:1379 ||| IN
clinical  ||| S:1379 E:1388 ||| JJ
symptoms ||| S:1388 E:1396 ||| NNS
.  ||| S:1396 E:1398 ||| .
The  ||| S:1398 E:1402 ||| DT
clinical  ||| S:1402 E:1411 ||| JJ
relevance  ||| S:1411 E:1421 ||| NN
of  ||| S:1421 E:1424 ||| IN
CMRI  ||| S:1424 E:1429 ||| NNP
abnormalities  ||| S:1429 E:1443 ||| NN
in  ||| S:1443 E:1446 ||| IN
patients  ||| S:1446 E:1455 ||| NNS
without  ||| S:1455 E:1463 ||| IN
clinical ||| S:1463 E:1471 ||| JJ
,  ||| S:1471 E:1473 ||| ,
echocardiographic  ||| S:1473 E:1491 ||| NN
and  ||| S:1491 E:1495 ||| CC
ECG  ||| S:1495 E:1499 ||| NNP
signs  ||| S:1499 E:1505 ||| NNS
of  ||| S:1505 E:1508 ||| IN
cardiac  ||| S:1508 E:1516 ||| JJ
involvement  ||| S:1516 E:1528 ||| NN
remains  ||| S:1528 E:1536 ||| VBZ
unknown  ||| S:1536 E:1544 ||| JJ
and  ||| S:1544 E:1548 ||| CC
needs  ||| S:1548 E:1554 ||| VBZ
to  ||| S:1554 E:1557 ||| TO
be  ||| S:1557 E:1560 ||| VB
evaluated  ||| S:1560 E:1570 ||| VBN
in  ||| S:1570 E:1573 ||| IN
future  ||| S:1573 E:1580 ||| JJ
studies ||| S:1580 E:1587 ||| NNS
.  ||| S:1587 E:1589 ||| .
It  ||| S:1589 E:1592 ||| PRP
seems  ||| S:1592 E:1598 ||| VBZ
premature  ||| S:1598 E:1608 ||| JJ
to  ||| S:1608 E:1611 ||| TO
intensify  ||| S:1611 E:1621 ||| VB
treatment  ||| S:1621 E:1631 ||| NN
or  ||| S:1631 E:1634 ||| CC
to  ||| S:1634 E:1637 ||| TO
prescribe  ||| S:1637 E:1647 ||| VB
systematically  ||| S:1647 E:1662 ||| JJ
steroids  ||| S:1662 E:1671 ||| NNS
and  ||| S:1671 E:1675 ||| CC
cytotoxic  ||| S:1675 E:1685 ||| JJ
agents  ||| S:1685 E:1692 ||| NNS
based  ||| S:1692 E:1698 ||| VBN
on  ||| S:1698 E:1701 ||| IN
the  ||| S:1701 E:1705 ||| DT
presence  ||| S:1705 E:1714 ||| NN
of  ||| S:1714 E:1717 ||| IN
isolated  ||| S:1717 E:1726 ||| JJ
CMRI  ||| S:1726 E:1731 ||| NNP
anomalies ||| S:1731 E:1740 ||| NN
.  ||| S:1740 E:1742 ||| .
